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TreatmentThis Editorial introduces the 2015 Open Thematic Series
dedicated to Cluster Headache (CH) and other Rare
Headaches. For too long researchers have focused their
attention on other most popular, sometimes clumsy or
foggy forms of headache, overlooking this important and
quasi-rare headache disorder [1].
Apparently CH represents the most peculiar form
among the Trigeminal Autonomic Cephalalgias (TACs).
The unbearable periorbital side-locked pain is coupled
by ipsilateral cranial autonomic symptoms (conjunctival
injection, lacrimation and rhinorrhea) and causes a vast
disability although the overall burden of this disease has
not yet found a complete systematization.
Especially its chronic form, characterized by more days
with attacks than not in the year span, represents a strict
minority (10 % of CH, 0,01 % overall) and hits 70.000 on a
sample of 100 millions of people. Even if these numbers
are relatively small the impact of this disease is destruc-
tive, thus CH represents a niche worth to be re-focused.
Recently Chronic CH (CCH) refractory to whichever
medical therapy (rCCH) has been systematized from a
clinical point of view [2].
The personal burden caused by CH, meant as loss of
employment, homebound days and disability is higher in
women than in men [3].
CH lifetime prevalence is 1/1000 and over the past de-
cades a progressive reduction of the male/female ratio
has been reported, being now 2.1:1 [4]. Even if CH is
easy to diagnose on the basis of its peculiar features, the
timing over the day of the attacks (up to 8), a temporally
defined active cluster period (60–90 days) and its seasonal* Correspondence: dimosmitsikostas@me.com
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in any medium, provided the original work is precurrence, only 1/3 of these patients is rightly diagnosed,
with an unacceptable delay of 5.3 years and consequently
more than 2/3 of them never receive a correct treatment
[1, 5, 6].
Actually the current pathophysiological theory of CH
is oriented towards a posterior hypothalamic dysfunction
[7] but further pharmacological studies shall selectively
focus this area. Recently the allele G of the G1246A
HCRTR2 polymorphism was been found to be associ-
ated with CH, indicating that hypocretin/orexin system’s
peptides may be involved in the transmission of pain, in
autonomic and neuroendocrine functions, and in the
pathogenesis of CH [8, 9].
For too many years sumatriptan, verapamil and corti-
costeroids have been the cornerstones of CH treatment
[1]; we hope that the starting era of monoclonal anti-
bodies against Calcitonin Gene-Related Peptide might
include CH as therapeutic target. An ongoing phase 3
RCT on the use of LY2951742 in episodic CH through
its preventative subcutaneous administration every 30 days
could change the future management of CH [10].
Other approaches to chronic cluster headache are the
new mini-invasive and non-invasive neuromodulation tech-
niques. The European Headache Federation recommends
caution in using these techniques [11] because only few
controlled studies have been carried out yet.
Among these new approaches, Vagal Nerve Stimuation
(VNS) and sphenopalatine ganglion stimulation (SPG)
seem promising but still classified at Class IV evidence
[12, 13]; SPG shows contrasting evidence [14]. All these
approaches need to be further confirmed and validated
by ad hoc RCTs.
Lastly, patients’ education is another important topic
to be re-considered: sleep pattern changes, alcoholicpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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diesterase inhibitors widely self-prescribed for erectile dys-
function trigger additional bouts during CH active phases
[1]. Furthermore, a more diffuse physicians education on
CH management should lead to an earlier diagnosis and a
more adequate treatment of this headache disorder [15].
Thus we trust that this Open Thematic Series dedicated
to Cluster Headache could thicken the attention on a
famed and quasi-rare headache disorder.
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